ADVA
20.12.2019 09:02:09 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that its FSP 150-XG480 has become the first 100Gbit/s solution on the market to achieve MEF 3.0 Carrier Ethernet certification. The compact metro edge device is now the industry’s only 100Gbit/s packet aggregation and demarcation technology proven to offer the highest available levels of performance, assurance and agility. With the ADVA FSP 150-XG480, enterprises and communication service providers (CSPs) can address the boom in cloud computing and mobile services by smoothly transitioning to 10 and 25Gbit/s service aggregation. What’s more, ADVA’s MEF 3.0-compliant technology enables them to meet the need for high-capacity wholesale, mobile and business services with a solution that supports automated networking and 5G-ready architectures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191220005017/en/
“CSPs now have the power to tackle the demand for 100Gbit/s aggregation at the metro edge with a solution guaranteed to deliver the highest industry standards for performance and assurance. With our unique technology, there’s now a simple and extremely cost-efficient route to MEF 3.0-certified 100Gbit/s service aggregation,” said James Buchanan, GM, Edge Cloud, ADVA. “Higher speeds in the access network are becoming essential. In fact, with the emergence of more and more connected devices as well as the unprecedented surge in video streaming platforms, 10Gbit/s is becoming the new 1Gbit/s. What our FSP 150-XG480 offers is a future-proof way to deliver MEF CE services up to 100Gbit/s and enable the efficient and reliable aggregation of multiple 10Gbit/s streams.”
The compact and powerful ADVA FSP 150-XG480 aggregator with high-density 1, 10 and 25Gbit/s port count is the ultimate tool for fighting bandwidth bottlenecks and evolving metro networks to 100Gbit/s. Its MEF 3.0-compliant interfaces and operation and management capabilities enable seamless integration into existing networks and established processes. The ADVA FSP 150-XG480 offers a range of advantages for connectivity and synchronization in mobile backhaul networks. These include leveraging ADVA’s Oscilloquartz Syncjack™ technology to constantly control the accuracy of network timing. It’s also the only device available with 100Gbit/s line-rate service activation and testing, so there’s no need for CSPs to compromise on high-value SLA-based business services.
“Achieving MEF 3.0-compliant status with our FSP 150-XG480 highlights the leading role ADVA continues to play in the Carrier Ethernet space. This certification is also great news for enterprises across the world as well as mobile network operators looking to meet soaring data demand. Now they can map 10 and 25GbE into 100Gbit/s aggregated bandwidth with a solution that easily expands to meet the coming requirements of 5G networks,” commented Eli Angel, VP, product line management, Ethernet access, ADVA. “Our FSP 150-XG480 is the key to future scalability. It also features an incredibly small form factor and environmentally hardened design, delivering a significant cost advantage over competing technology.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191220005017/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom